tetano
Editor, Senior Moderator
Sci Rep
. 2022 Mar 10;12(1):3954.
doi: 10.1038/s41598-022-07960-4.
Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern
Amanda J Griffin[SUP] 1 [/SUP], Kyle L O'Donnell[SUP] 1 [/SUP], Kyle Shifflett[SUP] 1 [/SUP], John-Paul Lavik[SUP] 2 [/SUP], Patrick M Russell[SUP] 2 [/SUP], Michelle K Zimmerman[SUP] 2 [/SUP], Ryan F Relich[SUP] 2 [/SUP], Andrea Marzi[SUP] 3 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) results in a variety of clinical symptoms ranging from no or mild to severe disease. Currently, there are multiple postulated mechanisms that may push a moderate to severe disease into a critical state. Human serum contains abundant evidence of the immune status following infection. Cytokines, chemokines, and antibodies can be assayed to determine the extent to which a patient responded to a pathogen. We examined serum and plasma from a cohort of patients infected with SARS-CoV-2 early in the pandemic and compared them to negative-control sera. Cytokine and chemokine concentrations varied depending on the severity of infection, and antibody responses were significantly increased in severe cases compared to mild to moderate infections. Neutralization data revealed that patients with high titers against an early 2020 SARS-CoV-2 isolate had detectable but limited neutralizing antibodies against the emerging SARS-CoV-2 Alpha, Beta and Delta variants. This study highlights the potential of re-infection for recovered COVID-19 patients.
. 2022 Mar 10;12(1):3954.
doi: 10.1038/s41598-022-07960-4.
Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern
Amanda J Griffin[SUP] 1 [/SUP], Kyle L O'Donnell[SUP] 1 [/SUP], Kyle Shifflett[SUP] 1 [/SUP], John-Paul Lavik[SUP] 2 [/SUP], Patrick M Russell[SUP] 2 [/SUP], Michelle K Zimmerman[SUP] 2 [/SUP], Ryan F Relich[SUP] 2 [/SUP], Andrea Marzi[SUP] 3 [/SUP]
Affiliations
- PMID: 35273264
- PMCID: PMC8913826
- DOI: 10.1038/s41598-022-07960-4
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) results in a variety of clinical symptoms ranging from no or mild to severe disease. Currently, there are multiple postulated mechanisms that may push a moderate to severe disease into a critical state. Human serum contains abundant evidence of the immune status following infection. Cytokines, chemokines, and antibodies can be assayed to determine the extent to which a patient responded to a pathogen. We examined serum and plasma from a cohort of patients infected with SARS-CoV-2 early in the pandemic and compared them to negative-control sera. Cytokine and chemokine concentrations varied depending on the severity of infection, and antibody responses were significantly increased in severe cases compared to mild to moderate infections. Neutralization data revealed that patients with high titers against an early 2020 SARS-CoV-2 isolate had detectable but limited neutralizing antibodies against the emerging SARS-CoV-2 Alpha, Beta and Delta variants. This study highlights the potential of re-infection for recovered COVID-19 patients.